Heme Oxygenase-1 (HO-1/HMOX1) is a stress-responsive enzyme that degrades heme into biliverdin, carbon monoxide (CO), and free iron. While HO-1 has well-established cytoprotective effects through antioxidant bilirubin production and anti-inflammatory CO signaling, its role in neurodegeneration is complex—chronic upregulation can release iron that promotes oxidative damage. Therapeutic modulation of HO-1 therefore requires careful consideration of disease context and timing.
Therapeutic strategies include HO-1 inducers (to boost innate antioxidant defenses) and CO-releasing molecules (CORMs) (to deliver the beneficial effects of CO without heme degradation). Both approaches have shown promise in preclinical models of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD)[@schipper2019].
HO-1 modulation offers multiple therapeutic benefits:
| Mechanism | Effect | Disease Relevance |
|---|---|---|
| Bilirubin production | Potent antioxidant, scavenges peroxyl radicals | AD, PD oxidative stress |
| Carbon monoxide (CO) | Anti-inflammatory, anti-apoptotic, vasodilatory | Neuroinflammation protection |
| Ferritin induction | Sequesters free iron, prevents Fenton chemistry | Iron overload in PD |
| Nrf2 pathway activation | Coordinated antioxidant response | Broad neuroprotection |
Alzheimer's Disease: HO-1 is markedly upregulated in AD brain tissue, particularly in association with neurofibrillary tangles and amyloid plaques[@smith1994]. While this represents a compensatory antioxidant response, the resulting iron release may contribute to amyloid-iron interactions that accelerate aggregation. HO-1 inducers that increase bilirubin generation may provide net neuroprotection in early AD stages.
Parkinson's Disease: HO-1 is highly expressed in dopaminergic neurons of the substantia nigra in PD[@schipper1998]. The enzyme colocalizes with α-synuclein in Lewy bodies. Therapeutic strategies aim to enhance the protective effects (bilirubin, CO) while managing iron release through combination with ferritin inducers or iron chelators.
Amyotrophic Lateral Sclerosis: HO-1 expression is elevated in spinal cord motor neurons of ALS patients and in SOD1 transgenic mice. HO-1 inducers have demonstrated neuroprotection in ALS models through anti-inflammatory and antioxidant mechanisms[@kim2009].
Huntington's Disease: HO-1 is induced in response to mutant huntingtin toxicity. CO-releasing molecules have shown benefit in HD models by reducing oxidative stress and neuroinflammation[@cabezas2007].
Hemin is a potent pharmacological inducer of HO-1 expression that has been studied extensively in neurodegenerative models.
Biliverdin is the primary product of HO-1 enzymatic activity and can be administered directly to bypass the iron-releasing step.
Curcumin is a natural polyphenol with well-documented HO-1 inducing properties.
Sulforaphane is an isothiocyanate found in cruciferous vegetables that potently induces HO-1 via Nrf2 activation.
CORMs are designed to deliver therapeutic CO without the complications of heme degradation.
A prototypical CO-releasing molecule that has been extensively studied in neurodegeneration models.
A water-soluble CORM with improved pharmacological properties.
A novel CORM designed for targeted CNS delivery.
HO-1 inhibitors are primarily used as research tools to understand HO-1's role in disease, though they may have therapeutic potential in iron-overload states.
| Compound | Mechanism | Status |
|---|---|---|
| Tin protoporphyrin (SnPP) | Competitive inhibitor at heme-binding site | Research tool |
| Zinc protoporphyrin (ZnPP) | Competitive inhibitor | Research tool |
| OB-24 | Novel small-molecule inhibitor | Preclinical |
Note: Chronic HO-1 inhibition is generally not recommended for neurodegeneration due to the loss of protective biliverdin/bilirubin production.
| Drug/Agent | Company/Institution | Indication | Stage | Notes |
|---|---|---|---|---|
| Hemin | Various academic | ALS, PD | Phase 2 (terminated) | Limited BBB penetration |
| Sulforaphane | Various | AD, PD | Phase 2/3 | Multiple trials ongoing |
| Curcumin formulations | Numerous | AD | Phase 2/3 | Bioavailability challenges |
| Dimethyl fumarate (Tecfidera) | Biogen | MS, AD | Approved (MS) | Nrf2 activator, induces HO-1 |
HO-1 modulators may be most effective in combination with: